Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update
18 juil. 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy
28 juin 2022 07h00 HE
|
Decibel Therapeutics, Inc.
- 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020-treated ear – - Data support continued development of DB-020 as a potential...
Decibel Therapeutics to Present at the Jefferies Global Healthcare Conference
03 juin 2022 07h30 HE
|
Decibel Therapeutics, Inc.
BOSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Hearing Health Advocates Launch National Campaign Promoting the Value and Expertise of Hearing Professionals
02 juin 2022 11h04 HE
|
Hearing Industries Association
Washington D.C., June 02, 2022 (GLOBE NEWSWIRE) -- Today, a group of leading consumer organizations, hearing health professional organizations, hearing aid manufacturers and retailers launched a new...
Otonomy to Participate in the H.C. Wainwright Global Investment Conference
18 mai 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference
17 mai 2022 07h30 HE
|
Decibel Therapeutics, Inc.
BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting
12 mai 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update
09 mai 2022 16h04 HE
|
Otonomy, Inc.
Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected...
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting
02 mai 2022 07h30 HE
|
Decibel Therapeutics, Inc.
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update
02 mai 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will...